Arrowhead price target raised to $55 from $50 at B. Riley

B. Riley raised the firm’s price target on Arrowhead Pharmaceuticals to $55 from $50 and keeps a Buy rating on the shares post the fiscal Q1 report. The company provided key corporate updates reflective of its increased focus on the most attractive pipeline candidates, notably within the cardiometabolic, pulmonary, and neuromuscular therapeutic categories, the analyst tells investors in a research note.